abstract |
The present invention relates to quinoline amide compounds of the formula (I) which are positive allosteric modulators of the M1 receptors and which are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain disorders or sleep disorders. The invention also relates to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor. |